Method for treating local and distant tumors
AssigneeIntraAb, Inc.
InventorsLijun Wu, Vita Golubovskaya
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method for treating cancer by delivering lipid-nanoparticles (LNPs) encapsulating immunostimulant mRNA and bispecific antibody mRNA to cancer cells or intratumorally. The method comprises the step of administering mRNA-encapsulated LNPs to a tumor lesion of a subject having cancer. The immunostimulant mRNA-LNP activates immune cells around tumor, which work together with mRNA-LNP encoding bispecific antibody and PBMC to effectively target local and distant metastatic tumors. Preferred immunostimulants are GM-CSF and IL-12, and its combination.
Claims20
A method for treating cancer, comprising the steps of:
- obtaining first lipid nanoparticles (LNPs) encapsulating a first mRNA that encodes a bispecific antigen-binding molecule comprising a first ScFv and CD3e ScFv, wherein said first scFv is against EPCAM, Her-2, Mesothelin, EGFR, PLAP, CD147, 4-1BB, c-Met, CD19/CD37, PSMA, CD47, CD19, BCMA, or Claudin 18.2;
- obtaining second LNPs encapsulating a second mRNA that encodes GM-CSF;
- obtaining third LNPs encapsulating a third mRNA that encodes IL-12;
- and
- administering the first, the second, and the third mRNA-encapsulated LNPs s to a tumor lesion of a subject having cancer.
A method for treating cancer, comprising the steps of:
- obtaining lipid nanoparticles (LNPs) encapsulating (a) a first mRNA that encodes a bispecific antigen-binding molecule comprising a first ScFv and CD3e ScFv, wherein said first scFv is against EPCAM, Her-2, Mesothelin, EGFR, PLAP, CD147, 4-1BB, c-Met, CD19/CD37, PSMA, CD47, CD19, BCMA, Claudin 18.2, (b) a second mRNA that encodes Gm-CSF, and (c) a third mRNA that encodes IL-12;
- administering the mRNA-encapsulated LNPs to a tumor lesion of a subject having cancer.
Dependencies are inferred from the claim text.